Sophie Blondel, Pharm D, PhD
About Sophie Blondel, Pharm D, PhD
Sophie Blondel, Pharm D, PhD, serves as the Associate Director and Global Program Development Leader at Sangamo Therapeutics, Inc. She has significant experience in cell and gene therapies, having held various leadership roles in program development across several organizations.
Work at Sangamo Therapeutics
Sophie Blondel serves as the Associate Director and Global Program Development Leader at Sangamo Therapeutics, Inc. since 2022. In this role, she focuses on advancing cell and gene therapies, leveraging her extensive experience in managing global program development initiatives. Her position is based in Nice, Provence-Alpes-Côte d’Azur, France, where she contributes to the strategic direction and execution of therapeutic programs.
Education and Expertise
Sophie Blondel holds a Doctor of Pharmacy degree from the Faculty of Pharmacy, Paris Descartes, which she completed from 2004 to 2010. She furthered her education at Université Paris-Saclay, earning a PhD in cell and molecular biology from 2010 to 2013. Additionally, she studied at the Faculté de médecine Pierre et Marie Curie (Paris VI), where she achieved a DU-GBM in the Value of Research and Biomedical Innovation in 2015. She has also pursued project management training, obtaining a Prince2-Project Management certification from Axelos Global Best Practice in 2019.
Background in Cell and Gene Therapies
Sophie Blondel has a substantial background in the field of cell and gene therapies. She began her career as a PhD student at I-Stem, focusing on stem cell research from 2010 to 2013. Following her doctoral studies, she worked at I-Stem as a Cell Therapy Project Manager from 2013 to 2016, and later held various roles at Yposkesi, including Senior Project Manager for Cell and Gene Therapy from 2018 to 2021 and Head of Innovation and Development Programmes for 10 months in 2021-2022. Her work encompasses both preclinical and clinical development phases.
Professional Experience
Sophie Blondel has held multiple positions in the biopharmaceutical industry. She worked at Sanofi as a Research Associate in 2010 and transitioned to I-Stem, where she contributed to stem cell research and cell therapy projects. At Yposkesi, she progressed from Cell Therapy Project Manager to Senior Project Manager and then to Head of Innovation and Development Programmes. Her diverse roles have equipped her with a comprehensive understanding of program development in the context of cell and gene therapies.